Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
IXAZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS – REAL WORLD EVIDENCE – EXPERIENCES OF THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES (KROHEM)
Josip Batinić, PhD (he/him/his)
attending physician
University Hospital Centre Zagreb; School of Medicine, University of Zagreb
Zagreb, Croatia